Comparison between treatment to edoxaban with apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in non-valvular atrial fibrillation patients in Germany: A retrospective cohort study
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Edoxaban (Primary) ; Apixaban; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2022 Results published in the International Journal of Cardiology
- 29 Oct 2020 New trial record
- 01 Sep 2020 Results comparing adherence and persistence in AF patients receiving QD versus BID NOAC regimens, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology